Our research group utilizes advanced computer software to predict the binding affinities of approved and experimental drugs for DNA. The extent of these binding interactions has a predictive value; we use it to estimate which groups in different drugs attach to specific regions in the DNA of cancer cells. Once we identify "scaffolds" present in different molecules, we produce new drugs by combining common features from different compounds to maximize DNA binding. The stronger the binding, the higher the likelihood of these drugs becoming imaging agents when they are marked with radioactive isotopes. Also, when we identify molecules with significant binding interactions, we test and evaluate in different settings looking for stronger inhibition of cancer initiation, progression and metastasis.